Population pharmacokinetics of micafungin in adult patients.

Population pharmacokinetics of micafungin in adult patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Population pharmacokinetics of micafungin in adult patients. Abstract Text:

Tawanda Gumbo,John Hiemenz,Lei Ma,James J Keirns,Donald N Buell,George L Drusano,Tawanda Gumbo,John Hiemenz,Lei Ma,James J Keirns,Donald N Buell,George L Drusano,

We performed population pharmacokinetic analysis of micafungin in adult patients treated with doses between 12.5 and 200 mg/day. Our analysis identified a breakpoint patient weight of 66.3 kg above which serum clearance increased by approximately 50%. Patients with weight >66.3 kg may need larger doses to achieve similar exposures to those <66.3 kg. However, the clinical implications are still unknown.

Population pharmacokinetics of micafungin in adult patients. Publishing Authors By Initials

T Gumbo,J Hiemenz,L Ma,JJ Keirns,D N Buell,GL Drusano,T Gumbo,J Hiemenz,L Ma,JJ Keirns,DN Buell,GL Drusano,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Population pharmacokinetics of micafungin in adult patients. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Diagnostic microbiology and infectious disease

VOLUME: 60

Page Numbers: 329-31

Journal Abbreviation: Diagn. Microbiol. Infect. Dis.

ISSN: 0732-8893

DAY: 19

MONTH: 11

YEAR: 2007

Population pharmacokinetics of micafungin in adult patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8305899

Population pharmacokinetics of micafungin in adult patients. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Population pharmacokinetics of micafungin in adult patients. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Population pharmacokinetics of micafungin in adult patients.

AFFILIATION: Ordway Research Institute, Albany, NY 12208, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Diagn Microbiol Infect Dis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Population pharmacokinetics of micafungin in adult patients Related Publications

• Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
• Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.
• Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
• Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
• In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
• Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of Nephrotoxicity.
• Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.
• Population pharmacokinetics of micafungin in adult patients.
• Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.
• Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.
• Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis.